Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02097277 | A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes | PHASE2 | COMPLETED | 219 | — | — | Apr 15, 2014 | May 17, 2016 | Jul 31, 2019 | 16 | United States, Canada |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.
| Arm | Type | Description |
|---|---|---|
| Treatment A: Placebo (Matching with BMS-986036 - Daily) | PLACEBO_COMPARATOR | Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks |
| Arm 2: Treatment B: BMS-986036 (1 mg Daily) | EXPERIMENTAL | BMS-986036 1 mg subcutaneous injection once daily for 12 weeks |
| Treatment C: BMS-986036 (5 mg Daily) | EXPERIMENTAL | BMS-986036 5 mg subcutaneous injection once daily for 12 weeks |
| Treatment D: BMS-986036 (20 mg Daily) | EXPERIMENTAL | BMS-986036 20 mg subcutaneous injection once daily for 12 weeks |
| Treatment E: BMS-986036 (20 mg Weekly) | EXPERIMENTAL | BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks |
| Name | Type | Description |
|---|---|---|
| BMS-986036 | BIOLOGICAL | - |
| Placebo (Matching with BMS-986036) | BIOLOGICAL | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0% * Body mass index 30.0 to 50.0 Exclusion Criteria: * Any significant acute or chronic medical il...